Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Clostridioides difficile toxin B (TcdB) is a major cytotoxin produced by the bacterium Clostridioides difficile. It is a potent inflammatory enterotoxin that causes epithelial cell damage, increased mucosal permeability, and acute tissue inflammation. TcdB acts by binding to host cell receptors, entering cells via endocytosis, and ultimately glucosylating Rho family GTPases, leading to actin cytoskeleton breakdown and cell death. It is a key virulence factor in C. difficile infections.
Glucosylation of Rho-family GTPases, leading to actin cytoskeleton disruption and cell death.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Clostridioides difficile toxin B (TcdB).